共 50 条
- [1] A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid LeukemiaBLOOD, 2018, 132Christian, SoniaPatel, PriteshAgrawal, VaibhavGriffin, ShawnCahill, KirkKhan, IrumSweiss, KarenShergill, ArdamanCalip, Gregory SampangStock, WendyOdenike, OlatoyosiKonig, HeikoQuigley, John G.
- [2] A Single Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) for Treatment of Patients with Relapsed or Refractory Acute Myeloid LeukemiaBLOOD, 2017, 130Christian, SoniaPatel, PriteshEsen, AysenurKhan, IrumSweiss, KarenGhanem, FaresSequeira, Christopher A.Shergill, ArdamanQuigley, John G.
- [3] A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemiaAMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) : 937 - 943Christian, SoniaArain, SaadPatel, PriteshKhan, IrumCalip, Gregory S.Agrawal, VaibhavSweiss, KarenGriffin, ShawnCahill, KirkKonig, HeikoEsen, AysenurShergill, ArdamanOdenike, OlatoyosiStock, WendyQuigley, John G.
- [4] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid LeukemiaBLOOD, 2012, 120 (21)Advani, AnjaliElson, PaulHsi, Eric D.Davis, RandallKalaycio, MattSobecks, RonaldCopelan, EdwardDuong, Hien K.Foster, BethanyRush, Mary LynnFarhat, LeslieSekeres, Mikkael A.
- [5] Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabineLEUKEMIA RESEARCH, 1999, 23 (08) : 695 - 700Raanani, PShpilberg, OGillis, SAvigdor, AHardan, IBerkowicz, MSofer, OLossos, IChetrit, ABen-Yehuda, DBell-Bassat, I
- [6] Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group study 2951JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2940 - 2947Wells, RJAdams, MTAlonzo, TAArceci, RJBuckley, JBuxton, ABDusenbery, KGamis, AMasterson, MVik, TWarkentin, PWhitlock, JA
- [7] APhase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid LeukemiaCLINICAL CANCER RESEARCH, 2019, 25 (14) : 4231 - 4237Advani, Anjali S.Cooper, BrendaVisconte, ValeriaElson, PaulChan, RickyCarew, JenniferWei, WeiMukherjee, SudiptoGerds, AaronCarraway, HettyNazha, AzizHamilton, BettySobecks, RonaldCaimi, PaoloTomlinson, BenjaminMalek, EhsanLittle, JaneMiron, AlexanderPink, JohnMaciejewski, JaroslawUnger, AllisonKalaycio, Mattde Lima, MarcosSekeres, Mikkael A.
- [8] Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (Meca) in refractory and relapsed acute leukemiaLEUKEMIA & LYMPHOMA, 2000, 39 (5-6) : 583 - 590Ferrá, CBerlanga, JJGallardo, DAncín, IMarín, DGonzález, JRPeris, JMuñoz, JSarrá, JGrañena, A
- [9] Salvage chemotherapy with mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC) in refractory or relapsed acute leukemia in adults.BLOOD, 2001, 98 (11) : 213B - 213BJang, JHLee, STHahn, JSKo, YWMin, YH
- [10] A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid LeukemiaBLOOD, 2023, 142Kuchroo, Manik RazdanRedd, Robert A.Garcia, Jacqueline S.Keng, MichaelHobbs, Gabriela S.Rosenblatt, JacalynLuskin, Marlise R.Narayan, RupaAmrein, Philip C.McMasters, MalgorzataWadleigh, MarthaHock, HannoStone, RichardNeuberg, Donna S.Avigan, DavidBallen, Karen K.Fathi, Amir T.DeAngelo, Daniel J.Brunner, Andrew M.